Tenax Therapeutics price target raised to $25 from $14 at Guggenheim

Guggenheim raised the firm’s price target on Tenax Therapeutics (TENX) to $25 from $14 and keeps a Buy rating on the shares. The firm is reiterating Tenax as a Top Pick for 2026 as it nears its first pivotal readout for oral levosimendan in pulmonary hypertension caused by heart failure with preserved ejection fraction in the second half of next year, the analyst tells investors.